GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 American Association for Cancer Research ("AACR") Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.

The first poster, entitled “BAT1706 demonstrates high similarity to Bevacizumab in comparative analysis with originator in Phase I clinical trials in New Zealand and China,” will highlight Phase I clinical data showing the biosimilarity between BAT1706, Bio-Thera’s bevacizumab biosimilar, and bevacizumab. An abstract of the presentation will be available on AACR website on the day of the presentation.

Presentation details are as follows:

Session Category:              Clinical Research

Session Title:                       Phase I Clinical Trials 2

Session Date and Time:  Monday, April 16, 2018, 8:00 AM - 12:00 PM

Location:                               McCormick Place South, Exhibit Hall A, Poster Section 42

Poster Board Number:        16

The second poster, entitled “BAT4306F, an anti-CD20 antibody devoid of fucose modification, demonstrates enhanced ADCC effect and potent in vivo efficacy,” will highlight preclinical data evaluating our novel ADCC-enhanced anti-CD20 mAb, which will begin a Phase I clinical trial later this year. An abstract of the presentation is currently available on AACR website.

Presentation details are as follows:

Session Category:             Immunology

Session Title:                     Therapeutic Antibodies, Including Engineered Antibodies 3

Session Date and Time:    Tuesday April 17, 2018 8:00 AM - 12:00 PM

Location:                             McCormick Place South, Exhibit Hall A, Poster Section 34

Poster Board Number:         13

Abstract Number:                    3823

Copies of both posters will be made available on the Company's website after they are presented.

About BAT1706

BAT1706 is an anticancer monoclonal antibody (mAb) biosimilar being developed to treat a variety of cancers, including non-small cell lung cancer, that are currently approved indications of the reference product, bevacizumab. BAT1706 has successfully completed preclinical development and two Phase I clinical trials. BAT1706 is currently being evaluated in a global Phase III clinical trial that will demonstrate the efficacy and safety of BAT1706 is similar to the reference product, bevacizumab.

About BAT4306F

BAT4306F is an investigational, monoclonal antibody targeting the CD20 receptor. The CD20 receptor is a validated drug target with monoclonal antibodies approved to treat lymphoma, rheumatoid arthritis, multiple sclerosis and lupus. BAT4306F is an ADCC-enhanced antibody that has demonstrated potent in vitro and in vivo efficacy in models of lymphoma. 

About Bio-Thera Solutions

Bio-Thera Solutions is a clinical-stage biopharmaceutical company focused on innovative therapeutics and biosimilars. Bio-Thera is developing a pipeline of ADCC-enhanced monoclonal antibodies, antibody-drug conjugates and best-in-class antibodies for the treatment of a broad range of cancers and other diseases. Bio-Thera’s biosimilar pipeline is focused on autoimmune and oncology therapeutics. The company is headquartered in Guangzhou, China and has more than 350 employees. Learn more at http://www.mjtiyu.com/EN/. Follow Bio-Thera Solutions on Twitter at @bio_thera_sol